ESMO 2021 | POLARIS: palbociclib for BIPOC patients with HER2-negative breast cancer

Gabrielle Rocque, MD, University of Alabama at Birmingham, Birmingham, AL, discusses the rationale and results of the POLARIS study, investigating the clinical outcomes and quality of life of black or indigenous people or people of colour (BIPOC) being treated with palbociclib for HER2-negative breast cancer. This part of the study focused on patients who are under-represented in clinical trials and compared their results to the general overall study population. The study found that palbociclib was well-tolerated and the results achieved by BIPOC patients were not significantly different to those achieved by the general study population. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.